杂交冠状动脉血运重建技术应用现状及展望

Current application status and prospect of hybrid coronary revascularization

杂交冠状动脉血运重建技术(HCR)结合冠状动脉旁路移植术(CABG)中左乳内动脉-左前降支(LIMA-LAD)旁路的远期通畅率优势及经皮冠状动脉介入治疗(PCI)的微创优势,为冠状动脉粥样硬化性心脏病患者提供了另一种再血管化治疗选择。绝大部分文献报道提示HCR可显著减小围术期创伤,在符合指征的患者中,可获得不亚于传统再血管化技术的中远期结果。本文基于该领域近10年来的国内外主要文献报道,总结了HCR技术的应用现状,探讨未来发展方向。

Hybrid coronary revascularization(HCR)combining with coronary artery bypass grafting(CABG)has a long-term patency of left internal mammary artery to left anterior descending artery(LIMA-LAD)grafting,and the percutaneous coronary intervention(PCI)has a minimal invasiveness.It provides an alternative revascularization for patients with coronary heart disease.For patients who meet the HCR indications,most studies suggest that HCR can significantly reduce perioperative trauma,and offer favorable mid-and long-term prognosis,which is comparable with traditional revascularization strategies.Based on the major research results in this field in the past 10 years,we review the current application status and discuss the potential future direction of HCR in this paper.